2022-11-08T07:41:45-06:00 2021-12-31 410746749 CLIFTONLARSONALLEN LLP 227 WEST TRADE STREET SUITE 800 CHARLOTTE NC 28202 990 2021-01-01 010648145 ORTHOCAROLINA RESEARCH INSTITUTE INC ORTH 7043232260 2001 VAIL AVENUE 300 CHARLOTTE NC 28207 CHRISTI CADD EXECUTIVE DIRECTOR 7043232260 2022-11-07 1 CHRISTI CADD 999009999 JOHN NORMAN P01506766 7049985200 2022-11-07 0 AAL1 IAL1 2021 2022-09-23 18:48:47Z CHRISTI CADD 2001 VAIL AVENUE 300 CHARLOTTE NC 28207 2910693 0 X WWW.ORTHOCAROLINARESEARCH.ORG X 2002 NC TO PROMOTE, DEVELOP AND CONDUCT STATE OF THE ART SCIENTIFIC RESEARCH AND EDUCATIONAL PROGRAMS FOR THE ADVANCEMENT OF ORTHOPEDIC CARE. OCRI WORKS BOTH INDEPENDENTLY AS WELL AS IN COLLABORATIONS WITH UNIVERSITIES, HOSPITALS, PHARMACEUTICAL AND DEVICE COMPANIES AND OTHER ACADEMIC AND RESEARCH ORGANIZATIONS TO FURTHER PROMOTE THE MISSION. 16 16 0 20 0 0 1258438 2015726 748260 889967 5 0 0 -6126 2006703 2899567 5000 160000 0 0 0 0 0 0 2332 2128587 2091473 2133587 2251473 -126884 648094 3763254 4697920 348634 277447 3414620 4420473 THE ORTHOCAROLINA RESEARCH INSTITUTE (OCRI) IS AN INDEPENDENT, NON-PROFIT 501(C)3 THAT EXISTS TO FACILITATE RELEVANT ORTHOPEDIC RESEARCH WHICH ADVANCES ORTHOPEDIC TREATMENTS, IMPROVES QUALITY OF LIFE FOR PATIENTS, AND EDUCATES THE MEDICAL COMMUNITY. 0 0 1532742 889967 THE INSTITUTE'S MISSION AND PRIORITIES ARE CENTRALLY FOCUSED ON (1) IMPROVED ORTHOPEDIC PATIENT CARE AND (2) HIGH QUALITY EVIDENCE-BASED RESEARCH TO DEVELOP NEW AND INNOVATIVE ORTHOPEDIC DEVICES AND TECHNOLOGIES WHOSE GOAL IS TO ANSWER CLINICAL QUESTIONS FOR IMPROVED OUTCOMES. THE INSTITUTE LEADS ONGOING FDA-REGULATED CLINICAL TRIALS AND INVESTIGATOR-INITIATED SCIENTIFIC ACADEMIC STUDIES. RESEARCH IS DISSEMINATED THROUGH PEER REVIEWED JOURNAL PUBLICATIONS WITH GREATER THAN 85 PUBLICATIONS ANNUALLY. 224831 160000 OPERATION WALK CAROLINAS PROVIDES HIP AND KNEE JOINT REPLACEMENT SURGERIES AT NO COST TO PATIENTS IN UNDERSERVED COUNTRIES WHO HAVE NO ACCESS TO THIS LEVEL OF CARE. IN ADDITION, THE MEDICAL TEAM SPENDS TIME TEACHING THE ORTHOPEDIC SURGEONS, NURSES, PHYSICAL THERAPISTS AND OTHER HEALTHCARE PROFESSIONALS IN THAT COUNTRY ON THE MOST ADVANCED TECHNIQUES AND TREATMENTS FOR DISEASES OF THE HIP AND KNEE JOINTS IN ORDER TO BETTER SERVE THEIR PATIENTS. HEALTHCARE PROFESSIONALS FROM THE CHARLOTTE AREA NON-PROFIT HOSPITAL SYSTEMS COLLABORATE WITH THE ORTHOCAROLINA PHYSICIAN TEAM TO COMPLETE SURGERIES ON THOSE MOST SEVERE CASES. 59210 THE INSTITUTE'S MISSION IS FOCUSED ON ADVANCING BOTH RESEARCH AND EDUCATION IN ORTHOPEDICS. THE ORTHOCAROLINA RESEARCH INSTITUTE HOSTS AN EDUCATIONAL CME (CONTINUING MEDICAL EDUCATION) SYMPOSIUM, KNOWN AS OSCAR MILLER DAY, FOR 350-400 ORTHOPEDIC PROVIDERS AND ALLIED HEALTH CARE PROFESSIONALS EACH YEAR. THIS SYMPOSIUM IS OVER 40 YEARS OLD AND IS MARKETED TO THE SOUTH EASTERN U.S. TOPICS ARE ROTATED ANNUALLY. 1816783 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 1 0 1 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 23 0 0 0 0 0 0 0 0 0 0 0 0 0 0 X 16 16 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 X CHRISTI CADD 7043232260 2001 VAIL AVENUE STE 300 CHARLOTTE NC 28207 WILLIAM GRIFFIN MD CHAIRMAN 1.50 X X 0 0 0 PATRICK M CONNOR MD DIRECTOR 0.10 X 0 0 0 WALTER B BEAVER MD DIRECTOR 0.10 X 0 0 0 JOHN L FRALEY JR DIRECTOR 0.10 X 0 0 0 RICHARD E THIGPEN DIRECTOR 0.10 X 0 0 0 FRED R JONES DIRECTOR 0.50 X 0 0 0 MORRY JOHNSTON DIRECTOR 0.10 X 0 0 0 CLENN GASTON MD DIRECTOR 0.50 X 0 0 0 CHARLES EAST III DIRECTOR 0.50 X 0 0 0 BRANDON BOYD DIRECTOR 0.10 X 0 0 0 VELVA WOOLEN DIRECTOR 0.10 X 0 0 0 HARVEY GANTT DIRECTOR 0.10 X 0 0 0 BRUCE DARDEN MD DIRECTOR 0.50 X 0 0 0 KENT ELLINGTON MD DIRECTOR 0.10 X 0 0 0 JOE HSU MD DIRECTOR 0.10 X 0 0 0 TOM SMITH DIRECTOR 0.50 X 0 0 0 CHRISTI CADD EXECUTIVE DIRECTOR 45.00 X 130590 0 28501 130590 0 28501 1 0 1 0 0 17239 1998487 160000 2015726 RESEARCH INCOME 541700 815625 815625 74342 74342 889967 5000 17239 11126 -6126 -6126 2899567 889967 0 -6126 160000 160000 19863 19863 745 745 21319 21319 35170 35170 5989 2178 3811 21923 21923 PAYROLL REIMBURSEMENT 1487192 1208256 278936 STUDY EXPENSES 289886 289886 OPWALK EXPENSES 64831 64831 OSCAR MILLER DAY EXPENS 59210 59210 85345 32422 50591 2332 2251473 1816783 432358 2332 558542 501818 198966 5087 700000 206193 391756 28164 34967 63378 63378 0 0 2755389 3048292 16000 16000 3763254 4697920 347309 277447 1325 348634 277447 X 2850957 3014342 563663 1406131 3414620 4420473 3763254 4697920 X 648094 357759 X 0 1 X 1 0 X 1128769 1118534 1804808 1258438 2015726 7326275 878272 863132 1383549 748260 889967 4763180 2007041 1981666 3188357 2006698 2905693 12089455 814292 691190 624256 509022 541573 3180333 367627 8524 352082 235526 963759 1181919 699714 624256 861104 777099 4144092 7945363 341184 10 14 5 0 341213 341184 10 14 5 341213 5000 5000 2348225 1981676 3188371 2006703 2910693 12435668 0.63890 0.60220 0.02740 0.04030 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 16000 1 13878 13878 0 49500 49500 0 0 BENEFICIAL INTEREST IN POOLED FUNDS 3048292 F 3048292 X 2916045 5352 11126 16478 2899567 0 2899567 2267951 5352 11126 16478 2251473 0 2251473 PART V, LINE 4: FOUNDATION FOR THE CAROLINAS, AN UNRELATED CHARITABLE ORGANIZATION, HOLDS POOLED FUNDS ON BEHALF OF THE INSTITUTE. THOSE FUNDS GENERATE INVESTMENT INCOME THAT IS USED FOR THE GENERAL SUPPORT OF THE INSTITUTE'S PROGRAM ACTIVITIES. PART X, LINE 2: THE INSTITUTE ADOPTED FASB GUIDANCE ON ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES. THE GUIDANCE CLARIFIES THE ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN AN ENTITY'S FINANCIAL STATEMENTS BY PRESCRIBING A RECOGNITION THRESHOLD AND MEASUREMENT ATTRIBUTE FOR THE FINANCIAL STATEMENT RECOGNITION AND MEASUREMENT OF A TAX POSITION TAKEN OR EXPECTED TO BE TAKEN. THE INSTITUTE'S POLICY IS TO RECORD A LIABILITY FOR ANY TAX POSITION TAKEN THAT IS BENEFICIAL TO THE INSTITUTE, INCLUDING ANY RELATED INTEREST AND PENALTIES, WHEN IT IS MORE LIKELY THAN NOT THE POSITION TAKEN BY MANAGEMENT WITH RESPECT TO A TRANSACTION OR CLASS OF TRANSACTIONS WILL BE OVERTURNED BY A TAXING AUTHORITY UPON EXAMINATION. MANAGEMENT BELIEVES THERE ARE NO SUCH POSITIONS AS OF DECEMBER 31, 2021 AND 2020 AND, ACCORDINGLY, NO LIABILITY HAS BEEN ACCRUED. PART XI, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES 11,126. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES 11,126. 0 0 0 0 0 0 0 0 0 0 ORTHOPEDIC REPLACEMENT SURGERIES CENTRAL AMERICA AND THE CARIBBEAN 20 160000 SURGICAL IMPLANT DEVICES 0 0 0 0 0 0 PART III ACCOUNTING METHOD: GOLF TOURNAMENT 22239 17239 5000 1044 9156 926 22239 17239 5000 1044 9156 926 11126 -6126 0 0 0 0 0 0 0 0 0 CHRISTI CADD EXECUTIVE DIRECTOR 118626 0 11964 0 0 0 5931 0 22570 0 159091 0 0 0 X 20 160000 RETAIL PRICE 0 0 0 FORM 990, PART VI, SECTION A, LINE 3 THE EXECUTIVE COMMITTEE IS COMPRISED OF THE CHAIRMAN OF THE BOARD, THE CHAIRMAN OF THE RESEARCH ADVISORY COMMITTEE AND THE EXECUTIVE DIRECTOR. ALL THREE POSITIONS ARE MEMBERS OF THE GOVERNING BOARD. FORM 990, PART VI, SECTION B, LINE 11B THE 990 DRAFT IS REVIEWED BY THE EXECUTIVE DIRECTOR FOLLOWED BY THE OCRI FINANCE AND AUDIT COMMITTEE. ONCE THE 990 IS IN ITS FINAL DRAFT, THE DOCUMENT IS CIRCULATED VIA EMAIL TO THE OCRI BOARD OF DIRECTORS FOR FINAL APPROVAL. ONCE CIRCULATED AND ALL COMMENTS HAVE BEEN CONSIDERED, THE FINAL VERSION IS SUBMITTED TO THE IRS. FORM 990, PART VI, SECTION B, LINE 12C THE EXECUTIVE DIRECTOR, BOARD MEMBERS AND KEY EMPLOYEES CERTIFY THAT THEY HAVE READ THE ORGANIZATION'S CONFLICT OF INTEREST POLICY AND HAVE DISCLOSED ANY RELATIONSHIPS WITH ANY OF THE ORGANIZATION'S CONTRACTING PARTIES ON THE ORGANIZATIONS CONFLICT OF INTEREST FORM. THE EXECUTIVE DIRECTOR REVIEWS THE CERTIFIED FORMS AND COMPARES IT TO THE PRIOR YEAR'S DISCLOSURES. QUESTIONABLE RELATIONSHIPS ARE NOTED AND BROUGHT TO THE ATTENTION OF THE APPROPRIATE GOVERNANCE GROUP. THE EXECUTIVE DIRECTOR DISCLOSES TO THE FINANCE AND AUDIT COMMITTEE ANY ITEMS THAT AFFECT BUSINESS COMPLIANCE DURING THE NEXT SCHEDULED MEETING AND DISCLOSES CONFLICTS RELATED TO THE RESEARCH TO THE RESEARCH ADVISORY COMMITTEE. APPROPRIATE STEPS ARE TAKEN TO ELIMINATE THE CONFLICT PER COMMITTEE GUIDANCE. FORM 990, PART VI, SECTION B, LINE 15 HUMAN RESOURCES DETERMINED INITIAL COMPENSATION BASED ON MARKET ANALYSIS FOR EXECUTIVE DIRECTOR POSITION. THE EXECUTIVE DIRECTOR RECEIVES THE SAME 3 TO 3.5% INCREASE AS ALL ORGANIZATION STAFF ON AN ANNUAL BASIS. THE HUMAN RESOURCE DEPARTMENT ESTABLISHES MIN, MID AND MAX SALARY RANGE FOR ALL POSITIONS IN OCRI BASED ON MARKET ANALYSIS. FORM 990, PART VI, SECTION C, LINE 19 GOVERNING DOCUMENTS, THE CONFLICTS OF INTEREST POLICY AND FINANCIALS STATEMENTS ARE PROVIDED UPON REQUEST. FORM 990, PART XI, LINE 9: CHANGE IN BENEFICIAL INTEREST IN POOLED FUNDS 357,759.